Elanco on Jan. 1 announced the completed acquisition of Novartis Animal Health. The acquisition, first announced in April, follows Elanco's purchase of Lohmann Animal Health earlier in 2014.
Elanco says both investments position the company to offer a more diversified product offering and capabilities to help customers sustain and grow their businesses. This includes the flagship brands and a portfolio of nearly 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes, food safety and more.
Going forward, Elanco says it will significantly increase investment in research and development. The combined organization will have expanded capabilities and expertise with a broader portfolio of more than 100 product development projects.
Elanco aims to help veterinarians help pets live longer, healthier lives, with pet ownership increasing as millions recognize the physical, social and emotional benefits of companionship. Elanco is also committed to helping producers around the world produce more food using fewer resources to meet the growing demand for animal protein while protecting the planet and well-being of animals.
"We'll continually seek innovative ways we can support our customers' business," said Rob Aukerman, president North American Commercial Operations for Elanco. "With increased technical services that combine our analytic and benchmarking tools with on-the-ground support, we'll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business."
For the foreseeable future, the businesses will continue in much the same way, including product ordering and customer support. Availability and access to products will continue uninterrupted, Elanco says.